Corticosteroid-binding globulin: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
Line 39: Line 39:
==Naturally-occurring genetic variants<ref>PMID: 19643161 </ref>==
==Naturally-occurring genetic variants<ref>PMID: 19643161 </ref>==


"Leuven"
''Leuven''
 
CBG Leuven has an exon 2 point mutation which changes Leucine 93 to a histidine, which reduces the binding affinity for cortisol by three-fold, although there appears to be no known clinical implications.
CBG Leuven has an exon 2 point mutation which changes Leucine 93 to a histidine, which reduces the binding affinity for cortisol by three-fold, although there appears to be no known clinical implications.


"Lyon"
''Lyon''
 
CBG Lyon has an exon 5 point mutation which changes Aspartate 367 to an asparagine.  This mutation lies close to the cortisol-binding pocket and reduces cortisol affinity by four-fold.  Heterozygotes show reduction in immunoreactive CBG levels and total cortisol levels but were otherwise healthy, while homozygotes presented with fatigue, depressed mood and low blood pressure.
CBG Lyon has an exon 5 point mutation which changes Aspartate 367 to an asparagine.  This mutation lies close to the cortisol-binding pocket and reduces cortisol affinity by four-fold.  Heterozygotes show reduction in immunoreactive CBG levels and total cortisol levels but were otherwise healthy, while homozygotes presented with fatigue, depressed mood and low blood pressure.


"CBG Null"
''CBG Null''
 
CBG Null is an exon 2 null mutation resulting in premature termination codon corresponding to residue -12 of pro-CBG molecule (G121A).  This leads to 50% (heterozygotes) or undetectable (homozygotes) CBG levels, and both hetero- and homozygotes presented with chronic fatigue and low blood pressure
CBG Null is an exon 2 null mutation resulting in premature termination codon corresponding to residue -12 of pro-CBG molecule (G121A).  This leads to 50% (heterozygotes) or undetectable (homozygotes) CBG levels, and both hetero- and homozygotes presented with chronic fatigue and low blood pressure


==Conclusion==
==Conclusion==